Acute Treatment of Traumatic Brain Injury

SanBio pic

Biotechnology executive Brian Frenzel is a director at SanBio, Inc., a cell therapy developer focusing primarily on neurodegenerative diseases. Under the leadership of Brian Frenzel, SanBio, Inc. has initiated research and development projects into traumatic brain injury (TBI).

TBI is a serious medical problem that can result in disability and death. Acute treatment following TBI usually focuses on life support and reducing secondary injuries that can arise from altered brain function. For example, physicians may insert a device in the brain cavity to stabilize intracranial pressure, or they may place the patient in a medically induced coma to minimize agitation. Acute treatments may also include mood stabilizers such as carbamazapine which can be used to control agitation, while atypical antidepressants such as amitryptyline can mitigate certain aggressive behaviors.

Other than physical therapy, there currently is no effective treatment for long term disability resulting from TBI. SanBio is developing a cell therapy product derived from mesenchymal stem cells to help patients recover from TBI disability. The product, known as SB623, is currently undergoing clinical studies in the US and Japan.